Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

NCT07009860 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT07009860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07009860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Lead sponsor
Altimmune, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 16, 2025
Completion date
September 30, 2027
Enrollment
121 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol-associated liver disease